Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo

Journal of Immunological Methods

Volumn 248, Issue 1-2, 2001, Pages 167-182

  Wallace, Paul K ^a   Kaufman, Peter A ^a   Lewis, Lionel D ^a   Keler, Tibor ^b   Givan, Alice L ^a   Fisher, Jan L ^a   Waugh, Mary G ^a   Wahner, Andrea E ^a   Guyre, Paul M ^a   Fanger, Michael W ^a   Ernstoff, Marc S ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

^b MEDAREX INC   (United States)

Author keywords

ADCC; Bispecific antibody; Fc receptor for IgG; HER 2 neu; Phagocytosis

Indexed keywords

BISPECIFIC ANTIBODY; GAMMA INTERFERON; MDX H210; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BONE MARROW CELL; BREAST ADENOCARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VIVO STUDY; MONOCYTE; ONCOGENE NEU; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; TARGET CELL DESTRUCTION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BREAST NEOPLASMS; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; MICE; MONOCYTES; NEOPLASMS; NEUTROPHILS; PHAGOCYTOSIS; RECEPTOR, ERBB-2; RECEPTORS, IGG; TUMOR CELLS, CULTURED;

EID: 0035251730     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00350-1     Document Type: Article

References (54)

1. Mechanisms of phagocytosis in macrophages
2. Phagocytosis mediated by three distinct Fcγ receptor classes on human leukocytes
3. Functional capacity of Fc gamma receptor III (CD16) on human neutrophils
4. Bispecific-armed, IFNγ-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma
5. Cytotoxicity mediated by human Fc receptors for IgG
6. Bispecific antibodies
7. Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor FcγRI (CD64) expressed on human blood dendritic cells
8. Fcγ receptor-mediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr, and Lyn
9. Human neutrophil Fc gamma receptor distribution and structure
10. 2 antibody containing thioether-linked Fab′γ fragments
11. Enhanced antigen presentation using human FcγR (monocyte/macrophage)-specific immunogens
12. Construction and characterization of a humanized anti-gamma-immunoglobulin receptor type I (FcγRI) monoclonal antibody
13. Characterization of a new monoclonal anti-FcγRII antibody, AT10, and its incorporation into a bispecific F(ab′)2 derivative for recruitment of cytotoxic effectors
14. Studies on the mechanism of phagocytosis. II. The interaction of macrophages with anti-immunoglobulin IgG-coated bone marrow-derived lymphocytes
15. Studies on the mechanism of phagocytosis. I. Requirement for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane
16. Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes
17. Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function
18. Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody responses in transgenic mice
19. The molecular dissection of Fc gamma receptor mediated phagocytosis
20. Her-2/neu targeted immunotherapy: A pilot study of multi-dose MDX-210 in patients with breast or ovarian cancers that overexpress HER-2/neu and a report of an increased incidence of HER-2/neu overexpression in metastatic breast cancer
21. Phase I trial of interferon gamma (IFNγ) and MDX-210 (anti-HER-2/neu×anti-anti FcγRI) in patients with metastatic carcinomas that overexpress HER-2/neu: Preliminary findings
22. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fcγ receptor type I-expressing effector cells
23. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules
24. Characterization of the family of dimers associated with Fc receptors (FcεRI and FcγRIII)
25. Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered with interferon gamma in a multiple dose phase-I study to patients with advanced solid tumors that overexpressed Her-2/neu
26. Class I-restricted presentation of exogenous antigen acquired by Fcγ receptor-mediated endocytosis is regulated by dendritic cells
27. Redirected targeting of LDL to human monocyte Fc gamma receptors with bispecific antibodies
28. Cytokine regulation of human monocyte differentiation in vitro: The tumor cytotoxic phenotype induced by macrophage colony stimulating factor is developmentally regulated by gamma-interferon
29. Antibody-independent phagocytosis of tumor cells by human monocyte-derived macrophages cultured in recombinant macrophage colony-stimulating factor
30. Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages
31. Stability of HER-2/neu expression over time and at multiple metastatic sites
32. Immune interferon induces the receptor for monomeric IgG1 on human monocytic and myeloid cells
33. Modulation of human polymorphonuclear leukocyte IgG Fc receptors and Fc receptor-mediated functions by IFN-γ and glucocorticoids
34. Fc receptors: Rubor redux
35. Fc receptors
36. Fcγ Receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I restricted antigen presentation after immune complex internalization
37. Neutrophils express the high affinity receptor for IgG (FcγRI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor
38. Identity of BCA200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2
39. Protein tyrosine phosphorylation in leukocyte activation through receptors for IgG
40. Phase I trial of the bispecific antibody MDXH210 (anti-FcγR1 X anti-HER-2/neu) in hormone refractory prostate cancer patients whose cancer over overexpresses HER-2/neu
41. T cell-targeted cytotoxicity
42. CD66 and CD67 cluster workshop report
43. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
44. Preclinical studies with FcγR bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer
45. Involvement of the high-affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy
46. Phase Ia/Ib trial of bispecific antibody MDX210 (anti-HER-2/neu×anti-FcγRI) in patients with advanced breast or ovarian cancer that over-expresses the proto-oncogene HER-2/neu
47. Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications
48. FcR γ-chain is essential for both surface expression and function of human FcγRI (CD64) in vivo
49. Role of Fcγ receptors in cancer and infectious disease
50. Humanized mAb H22 binds the human high affinity Fc receptor for IgG (FcγRI), blocks phagocytosis and modulates receptor expression
51. Targeting antigen to FcγRI results in presentation in association with MHC Class I
52. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210